Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × atezolizumab × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4 Thoracic 2 Gynecologic 1 Breast 1

Conditions

Breast Neoplasms 46 Triple Negative Breast Neoplasms 36 Carcinoma, Non-Small-Cell Lung 9 Head and Neck Neoplasms 8 Carcinoma, Renal Cell 7 Ovarian Neoplasms 6 Neoplasms 5 Melanoma 5 Colorectal Neoplasms 5 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Carcinoma, Transitional Cell 4 Carcinoma, Hepatocellular 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Small Cell Lung Carcinoma 3 Sarcoma 3 Prostatic Neoplasms 3 Gastrointestinal Neoplasms 3 Carcinoma, Merkel Cell 3 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Lymphoma 2 Lung Neoplasms 2 Kidney Neoplasms 2 HER2-positive Breast Cancer 2 Endometrial Neoplasms 2 Vulvar Neoplasms 1 Urologic Neoplasms 1 Urologic Diseases 1

Interventions

Cyclophosphamide 6 Radiotherapy 5 olaparib 3 Paclitaxel 3 Letrozole 3 Itraconazole 3 Carboplatin 3 Blood Specimen Collection 3 palbociclib 2 fludarabine phosphate 2 exemestane 2 eribulin 2 avelumab 2 abemaciclib 2 Therapeutics 2 Polymerase Chain Reaction 2 Peripheral Blood Stem Cell Transplantation 2 Melphalan 2 Mastectomy 2 Gemcitabine 2 Fulvestrant 2 Flow Cytometry 2 Exercise 2 Etoposide 2 Cetuximab 2 Carmustine 2 Bevacizumab 2 Antilymphocyte Serum 2 Anastrozole 2 Amplified Fragment Length Polymorphism Analysis 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04739670 2024-03-01

BELLA

Peter MacCallum Cancer Centre, Australia

Phase 2 Unknown

Recurrence, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡